BridgeBio Pharma, Inc. today announced that on March 7, 2023, the compensation committee of BridgeBio’s board of directors granted five new employees restricted stock units for an aggregate of 25,900 shares of the Company’s common stock.
Following the U.S. Food and Drug Administration’s decision , Covis Pharma Group (“Covis”) is effectuating the withdrawal of Makena ® (hydroxyprogesterone caproate injection), which has been the only treatment approved to reduce the risk of preterm birth in pregnant women who have had a prior spontaneous preterm birth.
Covis Statement on FDA Decision to Withdraw Approval of Makena® Read More »
Merck, known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.
Mabwell, an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset demonstrated promising clinical data.
China’s First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released Read More »
Al día de hoy es probable que ninguna persona haya dejado de tener un acercamiento a las farmacias online. Este tipo de negocios permite acceder a medicamentos y productos farmacéuticos al alcance de la mano. De manera fácil, rápida y segura se adquiere cualquie …
Farmacias online: ¿cómo elegir una adecuada para ti? Read More »
AnPac Bio-Medical Science Co., Ltd. announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs.
AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering Read More »
Nuance Pharma announces dosing of first patient in the ENHANCE – China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.
Readers for Abbott’s FreeStyle Libre glucose monitoring systems could catch fire if improperly stored or charged, the FDA says.
Abbott faces Class I recall of 4.2M glucose readers on battery fire risks Read More »
If funding in the next three quarters matches the average funding in the prior three, 2023 is on pace to see the lowest level of digital health funding since 2019, a new report from Rock Health found.
‘Turbulent waters’: The rocky digital health funding market post SVB collapse Read More »
Torrent Pharma has begun shipping the generic version of Xeris’s Keveyis® (dichlorphenamide), 50mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
